Analyst firms · Leerink Partners · HCAT

Leerink Partners HCAT price target and rating history

Health Catalyst Inc (HCAT) · Technology

Leerink Partners rates Health Catalyst Inc (HCAT) Outperform with a $48 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on HCAT since June 2021, including 0 upgrades and 0 downgrades.

Current rating
Outperform
Price target
$48
Median target, all firms
Too few
Actions on HCAT
3

Leerink Partners price target on HCAT

$64$56$4820222023202420252026
Leerink Partners price target on HCAT, each point a stated target, June 2021 to March 2022.

Every Leerink Partners rating on HCAT

How other firms rate HCAT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Canaccord GenuityHold$1.80Aug 21, 2026
Wells FargoEqual Weight$1Mar 18, 2026

Questions about Leerink Partners and HCAT

What is Leerink Partners's price target for HCAT?
Leerink Partners's latest stated price target for Health Catalyst Inc (HCAT) is $48, from its action on Mar 2, 2022.
What is Leerink Partners's rating on HCAT?
Leerink Partners rates HCAT Outperform, a bullish rating, as of Mar 2, 2022.
When did Leerink Partners last change its view on HCAT?
On Mar 2, 2022, Leerink Partners cuts its price target to $48 from $64, keeps Outperform.

More HCAT rating histories

All Leerink Partners ratingsHCAT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.